• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

STALICLA SA

Tuesday, June 04, 2024
Company Presentation
CNS/Neurological
Company Presentation Theater 3
Stalicla, a global biotech firm, specializes in advancing precision medicine for brain diseases. Since 2017, it has raised $75M in private capital, with key shareholders including Novartis, Pictet, Edmond de Rothschild, and SPRIM. Stalicla's neuro precision platform, DEPI, focuses on Autism Spectrum Disorder, with two assets, STP1 and STP2, entering Phase 2. Additionally, STP7, licensed from Novartis, is in Phase III trials for substance use disorders, offering opportunities in the wider CNS field. STALICLA is preparing a $75M Series C to support Phase 2 trials, develop STP7, and expand its pipeline, with $24M secured for a new Phase II asset.
STALICLA SA
Company Website: https://stalicla.com
Lead Product in Development: STP7 (mavoglurant, in licensed from Novartis): a mGluR5 negative allosteric modulator platform with strong potential for neuropsychiatric disorders and other CNS indications. First indication for STP7 includes cocaine and alcohol use disorder and it is being advanced with the partnership of the NIH with a cocaine use disorder Phase 3 in 2025.

Company HQ City

Geneva

Company HQ State

Geneve

Company HQ Country

Switzerland

CEO/Top Company Official

Lynn Durham CEO & Founder

Development Phase of Primary Product

Phase II
Primary Speaker
Lynn Durham
CEO & Founder
STALICLA SA
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS